- Business Wire•14 hours agoAcceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. and Celgene Corporation today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in patients with beta-thalassemia during an oral presentation at the 58th Annual Meeting of the American Society of Hematology in San Diego, California.
- Investopedia•17 hours ago
Acceleron and Celgene are launching an ambitious trial to find a cure for a cancer-like blood disorder that will eliminate the need for blood transfusions.
- Zacks•21 hours ago
Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.
XLRN : Summary for Acceleron Pharma Inc. - Yahoo Finance
Acceleron Pharma Inc. (XLRN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Ask||45.25 x 100|
|Day's Range||33.28 - 37.22|
|52 Week Range||22.67 - 50.86|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-19.70|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|